BNY Mellon US Mid Cap Core Equity ETF (BKMC) has seen unusual trading volume, which is 38× higher than its average daily volume.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Among BKMC’s top positions, United Therapeutics Corp. has drawn attention after multiple Wall Street firms sharply raised their price targets, citing stronger-than-expected Phase 3 TETON‑1 trial data that bolster the case for expanding Tyvaso to treat idiopathic pulmonary fibrosis, though several analysts are balancing this optimism with valuation and execution risks and maintaining Hold or Neutral ratings. MasTec Inc. also saw a positive analyst revision, with Barclays lifting its price target and reiterating an Overweight rating as it updates outlooks across the machinery and construction space. Fabrinet, another notable holding, is under pressure as investors take profits following a strong rally, with some analysts warning that the stock appears overbought and richly valued versus peers, raising concerns about whether its elevated valuation is sustainable.